GW Pharmaceuticals PLC- (NASDAQ:GWPH) Rating Lowered to Hold at Zacks Investment Research

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

Other analysts also recently issued reports about the stock. Cowen reissued a “buy” rating and set a $200.00 price target on shares of GW Pharmaceuticals PLC- in a report on Friday, July 26th. Bank of America reaffirmed a “buy” rating and set a $218.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Wednesday, September 25th. ValuEngine raised shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Wednesday, September 4th. Morgan Stanley increased their price objective on shares of GW Pharmaceuticals PLC- to $238.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Finally, Oppenheimer decreased their price objective on shares of GW Pharmaceuticals PLC- from $239.00 to $233.00 and set an “outperform” rating on the stock in a report on Friday, September 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $214.20.

NASDAQ:GWPH opened at $118.11 on Friday. The firm has a market capitalization of $3.68 billion, a P/E ratio of -11.18 and a beta of 2.23. GW Pharmaceuticals PLC- has a 1-year low of $90.14 and a 1-year high of $196.00. The company’s fifty day moving average price is $127.45 and its 200-day moving average price is $158.03. The company has a debt-to-equity ratio of 0.03, a current ratio of 8.31 and a quick ratio of 7.59.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.96. GW Pharmaceuticals PLC- had a negative net margin of 101.45% and a negative return on equity of 38.09%. The firm had revenue of $72.04 million for the quarter, compared to the consensus estimate of $37.28 million. During the same period in the prior year, the firm posted ($0.25) earnings per share. The firm’s quarterly revenue was up 2096.3% compared to the same quarter last year. Equities analysts anticipate that GW Pharmaceuticals PLC- will post -3.94 EPS for the current fiscal year.

In related news, insider Douglas B. Snyder sold 3,756 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $13.88, for a total transaction of $52,133.28. Following the completion of the sale, the insider now directly owns 79,164 shares in the company, valued at $1,098,796.32. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Douglas B. Snyder sold 5,424 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $13.04, for a total transaction of $70,728.96. Following the sale, the insider now owns 73,740 shares of the company’s stock, valued at $961,569.60. The disclosure for this sale can be found here. 3.60% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. increased its position in GW Pharmaceuticals PLC- by 4.8% during the second quarter. Envestnet Asset Management Inc. now owns 2,014 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 92 shares during the last quarter. Close Asset Management Ltd increased its position in GW Pharmaceuticals PLC- by 13.5% during the second quarter. Close Asset Management Ltd now owns 876 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 104 shares during the last quarter. Aperio Group LLC increased its position in GW Pharmaceuticals PLC- by 4.0% during the second quarter. Aperio Group LLC now owns 2,763 shares of the biopharmaceutical company’s stock worth $476,000 after purchasing an additional 106 shares during the last quarter. D.A. Davidson & CO. increased its position in GW Pharmaceuticals PLC- by 3.3% during the second quarter. D.A. Davidson & CO. now owns 3,611 shares of the biopharmaceutical company’s stock worth $623,000 after purchasing an additional 117 shares during the last quarter. Finally, Rothschild Investment Corp IL increased its position in GW Pharmaceuticals PLC- by 0.7% during the second quarter. Rothschild Investment Corp IL now owns 17,689 shares of the biopharmaceutical company’s stock worth $3,049,000 after purchasing an additional 120 shares during the last quarter. Hedge funds and other institutional investors own 82.93% of the company’s stock.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Read More: How is a Moving Average Calculated?

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.